19 June 2017 - Takeda and TiGenix today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted for ...
19 June 2017 - Axovant Sciences today announced that the U.S. FDA has granted fast track designation to its investigational ...
19 June 2017 - FDA sets PDUFA target action date of 3 February 2018. ...
15 June 2017 - Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference ...
14 June 2017 - Novo Nordisk today announced the submission of a type II variation application to the EMA for including ...
6 June 2017 - Tafamidis, an investigational medicine for TTR-CM a rare, progressive and fatal disease, is currently in phase ...
5 June 2017 - BioCryst Pharmaceuticals announced today that the U.S. FDA has accepted for review the supplemental new drug ...
5 June 2017 - Amgen today announced the submission of a supplemental biologics license application to the U.S. FDA and a ...
1 June 2017 - Priority review voucher submitted in US with anticipated target action date of 6 months. ...
31 May 2017 - Applications seek to expand approved use of Sutent based on data from the Phase 3 S-TRAC trial. ...
31 May 2017 - Novo Nordisk today announced that the US FDA has approved the biologics license application for Rebinyn ...
31 May 2017 - U.S. patent protection until at least 2030. ...
31 May 2017 - Jazz Pharmaceuticals today announced that the U.S. FDA has accepted for filing with priority review its recently ...
31 May 2017 - QR-110 is currently in clinical development with the planned Phase 1/2 open-label trial (PQ-110-001) that will assess ...
31 May 2017 - These regulatory submissions follow soon after two positive CHMP opinions for Sandoz biosimilars etanercept and rituximab further ...